2 min readResearchers Identify New Anti-Tumour Gene
According to Dr. Paul B. Fisher, professor and chair of the Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine in the VCU School of Medicine, and lead investigator of the study, this novel gene highlights a previously unrecognized molecular pathway underlying the anti-tumour action of interferon, INF.
In the study, published online in the Dec. 8 issue of the Proceedings of the National Academy of Sciences, researchers report the discovery of a new gene named SARI, which was uncovered by a powerful technique pioneered in the Fisher laboratory known as subtraction hybridization.
SARI, which is induced by a potent immune system modulator called interferon, was found to suppress growth and survival of tumour cells by interfering with the action of cancer cell molecules that drive cell division and promote survival.
The investigators delivered SARI to cancer cells using a virus and the infected cancer cells subsequently stopped dividing and died. Since 90 percent of all cancer types rely on a similar mechanism to proliferate and evade destruction, Fisher noted that SARI could be an effective anti-cancer treatment for many tumours.
“Additionally, IFNs are powerful immune modulating agents that contribute to the immune response to cancer and they are effective inhibitors of new blood vessel formation, the process of angiogenesis, which is obligatory for the growth of both primary and metastatic cancers,” said Fisher, who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center.
Currently, IFNs are relevant in the clinical treatment of a number of solid tumours and hematological malignancies, such as melanoma, renal cell carcinoma, malignant glioma, lymphomas and leukemias, either as a monotherapy or as an adjuvant to chemotherapy or radiotherapy.
“We have uncovered a new way by which interferon can induce anti-tumour activity. The identification of SARI also provides a new potential reagent for the selective killing of tumour cells,” said Fisher. “
The present study indicates that interferon can suppress cancer growth by inhibiting expression of a cancer-dependent transcription factor that controls genes that regulate cancer cell growth. The SARI gene may provide novel and selective gene therapy applications for cancer. It could also prove amenable for inhibiting proliferative disorders that depend on AP-1 activity,” he said.
AP-1 plays a key role in regulating proliferation and transformation of cancer cells. The team is now developing improved approaches to more effectively target the delivery of SARI. Fisher said these studies will be crucial for exploiting the cancer-selective killing activity of this gene and enhancing its therapeutic applications.